CO₂-First Decision Algorithm for Peripheral Endovascular Procedures
In peripheral angiographic procedures performed below the diaphragm, the choice of contrast agent is a clinical decision with a direct impact on the patient's renal function. This article presents a step-by-step CO₂-first decision algorithm designed for vascular surgeons and interventional radiologists, with the objective of standardizing a CO₂-first approach, defining objective patient selection criteria, and identifying the clinical situations in which a controlled fallback using micro-doses of iodinated contrast is justified and fully documentable.
Why Adopt a CO₂-First Approach in Peripheral Endovascular Procedures
Contrast-associated acute kidney injury (CA-AKI) and post-procedural acute kidney injury (AKI) remain important complications in patients with chronic kidney disease (CKD), diabetes mellitus, or a history of hypersensitivity to iodinated contrast media. In patients with an eGFR below 45 mL/min/1.73 m², the risk of acute deterioration in renal function following contrast administration is significantly increased, with important consequences for hospital length of stay, healthcare costs, and long-term prognosis.
CO₂ is a physiologically occurring gas that is eliminated through respiration and has neither direct nephrotoxic effects nor allergenic potential. When used as a contrast agent for vascular procedures below the diaphragm, it provides diagnostically adequate image quality for most clinical indications, provided it is delivered using an automated injection system capable of ensuring controlled and reproducible pressure, volume, and flow rate.
CO₂-First Decision Algorithm: Step by Step
Step 1 – Pre-Procedural Patient Assessment
Before every peripheral vascular procedure, the following parameters should be collected: recent serum creatinine and eGFR values (preferably obtained within the previous seven days), the presence of insulin-dependent or non-insulin-dependent diabetes mellitus, any history of allergy or adverse reactions to iodinated contrast media, and cardiopulmonary conditions that may contraindicate the use of CO₂ (for example, documented right-to-left intracardiac shunts or severe pulmonary hypertension).
Based on this assessment, patients can be classified into three renal risk categories: low risk (eGFR ≥60 mL/min/1.73 m², no history of allergy, no significant cardiopulmonary disease), intermediate risk (eGFR 30–59 mL/min/1.73 m², diabetes without advanced CKD, mild history of contrast allergy), and high risk / mandatory contrast-sparing strategy (eGFR <30 mL/min/1.73 m², CKD stage 4–5, documented severe iodinated contrast allergy, patients on dialysis, or kidney transplant recipients).
Step 2 – Selecting CO₂ as the First-Line Contrast Agent
A CO₂-first strategy is recommended for all peripheral vascular procedures performed below the diaphragm in patients at intermediate or high renal risk. These include aortoiliac and femoropopliteal angiography, peripheral revascularization procedures (PTA and stenting), EVAR and other endovascular aortic interventions in patients with CKD, as well as evaluation and treatment of arteriovenous fistulas for hemodialysis. Even in low-risk patients, CO₂ may be considered as part of a broader contrast-sparing strategy aimed at reducing cumulative exposure to iodinated contrast media.
Step 3 – Technical Parameters for CO₂ Injection
An automated CO₂ injection system provides controlled and reproducible delivery parameters while eliminating the risk of over-injection associated with manual administration. Recommended initial settings for peripheral interventions include injection volumes of 20–30 mL for the iliac arteries and infrarenal aorta, and 10–20 mL for the femoropopliteal and distal arteries. Maximum injection pressure should generally range between 100 and 150 mmHg, with flow rates of 15–20 mL/s for the aorta and iliac arteries, reduced to approximately 8–12 mL/s for distal vessels. Patients should be positioned supine or in slight Trendelenburg position to facilitate gas distribution. Digital subtraction angiography (DSA) acquisition is preferably performed using a lower frame rate to optimize the signal-to-noise ratio characteristic of CO₂ imaging.
Step 4 – Intra-Procedural Image Quality Assessment
After each CO₂ acquisition, image quality should be evaluated in real time using objective diagnostic criteria, including visualization of the vascular lumen, identification of target lesions (stenoses, occlusions, and collateral vessels), definition of vessel margins, and the absence of artifacts caused by fragmentation of the gas bolus. If image quality is diagnostically adequate, the procedure should continue using CO₂. If image quality remains suboptimal, the predefined fallback protocol should be activated.
Step 5 – Objective Criteria for Fallback to Micro-Doses of Iodinated Contrast
Fallback to iodinated contrast is indicated when, despite optimization of CO₂ injection parameters, CO₂ imaging is unable to: reliably identify the vascular lumen or the target lesion, safely complete a critical interventional step (such as stent deployment or endograft sealing assessment), or distinguish between imaging artifacts and true vascular pathology. In these situations, diluted micro-doses of iodinated contrast (typically diluted 1:1 with normal saline) may be administered using predefined maximum volumes, with every administration documented in the patient's medical record.
The cumulative volume of iodinated contrast should be recorded in real time and should never exceed the individualized maximum threshold calculated according to the patient's body weight and renal function. One widely used reference formula is: Maximum contrast volume (mL) = 5 × body weight (kg) / serum creatinine (mg/dL). This calculation should be documented as part of the pre-procedural assessment.
Indications, Contraindications, and Common Errors in CO₂ Angiography
The following table is intended as a printable reference for use in the angiography suite or during multidisciplinary case discussions.
| Category | Details |
| Indications for CO₂ (Peripheral Procedures) | Aortoiliac and femoropopliteal angiography; peripheral percutaneous transluminal angioplasty (PTA) and stenting; EVAR in patients with CKD; evaluation of arteriovenous fistulas for hemodialysis; patients with iodinated contrast allergy; eGFR <45 mL/min/1.73 m². |
| Absolute Contraindications to CO₂ | Documented right-to-left intracardiac shunts; cerebral or coronary procedures; injection into the pulmonary circulation; use of non-medical or uncertified CO₂. |
| Relative Contraindications to CO₂ | Severe pulmonary hypertension; severe chronic obstructive pulmonary disease (COPD); supra-diaphragmatic visceral procedures; uncooperative or agitated patients. |
| Common Technical Errors | Uncontrolled manual injection (risk of over-distension); use without a certified automated injection system; failure to eliminate air from the circuit (contamination); DSA acquisition at excessively high frame rates; incorrect patient positioning. |
| Common Clinical Errors | Failure to document cumulative iodinated contrast volume during fallback; omission of individualized maximum iodinated contrast dose calculation; failure to reassess renal function after the procedure in high-risk patients. |
Documentation and Traceability Checklist for Clinical Audit
Comprehensive documentation of CO₂ injection parameters is essential for procedural traceability, multidisciplinary review, and evaluation of renal outcomes during follow-up. Automated CO₂ injection systems incorporate data logging functions that record injection volume, pressure, and flow rate for every individual injection, making traceability an integral part of the clinical workflow.
The recommended minimum documentation checklist includes:
- Pre-procedural eGFR and serum creatinine values (including date of measurement)
- Assigned renal risk category (low, intermediate, or high)
- Calculated maximum iodinated contrast dose documented in the medical record
- Total CO₂ volume administered during the procedure
- Cumulative iodinated contrast volume (if fallback was required)
- CO₂ injection parameters: maximum pressure, injection volume, and flow rate
- Documented clinical rationale for every episode of iodinated contrast fallback
- Assessment of CO₂ image quality (diagnostically adequate, suboptimal, or non-diagnostic)
- Renal function assessment performed 24–48 hours after the procedure in high-risk patients
Integration into the Multidisciplinary Care Pathway and Clinical Governance
Adoption of a CO₂-first protocol is not an individual operator initiative but requires multidisciplinary alignment among Vascular Surgery, Interventional Radiology, and Nephrology. Regular multidisciplinary review of cases, together with systematic documentation of renal outcomes, allows institutions to measure the real impact of contrast-sparing strategies, identify opportunities for workflow improvement, and build local evidence to support Health Technology Assessment (HTA) activities and structured technology adoption.
The availability of procedure-specific traceability—including CO₂ volume administered, iodinated contrast volume avoided, incidence of post-procedural AKI, and imaging quality—also provides the foundation for participation in multicenter registries and prospective clinical studies evaluating long-term renal outcomes.
How to Apply the CO₂-First Algorithm During a Peripheral Endovascular Procedure
Step 1: Assess the Patient's Pre-Procedural Renal Risk
Record the patient's eGFR, recent serum creatinine, history of iodinated contrast allergy, and relevant cardiopulmonary conditions. Classify the patient as low, intermediate, or high renal risk. Calculate the individualized maximum iodinated contrast dose using the formula: 5 × body weight (kg) / serum creatinine (mg/dL), and document the value before the procedure.
Step 2: Verify Technical Readiness for CO₂ Angiography
Confirm that the automated CO₂ injection system has been correctly prepared, ensuring the absence of air within the circuit, the use of certified medical-grade CO₂, and intact single-use consumables. Verify that the procedure is performed below the diaphragm, that no absolute contraindications exist, and configure the initial injection parameters (volume, pressure, and flow rate) according to the target vascular territory.
Step 3: Perform the First Diagnostic CO₂ Injection and Evaluate Image Quality
Acquire the DSA sequence following the initial CO₂ injection. Evaluate image quality in real time by assessing vessel lumen visualization, lesion identification, and the absence of non-interpretable artifacts. If diagnostic quality is adequate, continue the procedure using CO₂ while documenting each injection.
Step 4: Optimize Technical Parameters Before Considering Fallback
If image quality is suboptimal, verify patient positioning (supine or slight Trendelenburg), catheter position, DSA frame rate, injection volume, and flow rate before introducing iodinated contrast. Repeat the acquisition using optimized parameters. Activate the fallback strategy only if imaging remains non-diagnostic despite technical optimization.
Step 5: Apply Controlled Micro-Iodinated Contrast Fallback
Administer diluted iodinated contrast (1:1 with normal saline) using the minimum volume required to achieve diagnostic image quality. Immediately document the administered volume, the clinical indication for fallback, and the cumulative iodinated contrast volume. Verify that the total contrast dose remains below the individualized maximum threshold.
Step 6: Complete Documentation and Plan Renal Follow-Up
At the conclusion of the procedure, document the total CO₂ volume administered, total iodinated contrast volume, image quality for each vascular territory, and the rationale for every fallback episode. For high-risk patients, schedule renal function assessment within 24–48 hours. Share procedural data with the multidisciplinary team to support outcome monitoring and continuous quality improvement.
Frequently Asked Questions About the CO₂-First Algorithm in Peripheral Endovascular Procedures
For which peripheral procedures is CO₂ suitable as the primary contrast agent?
CO₂ is indicated as the primary contrast agent for vascular procedures performed below the diaphragm, including aortoiliac, femoropopliteal, and infrapopliteal angiography, peripheral percutaneous transluminal angioplasty (PTA) and stenting, endovascular aortic repair (EVAR), and evaluation of arteriovenous fistulas for hemodialysis. It is particularly appropriate for patients with chronic kidney disease (eGFR <45 mL/min/1.73 m²), diabetes mellitus, documented hypersensitivity to iodinated contrast media, or an increased risk of post-procedural acute kidney injury.
When is fallback to iodinated contrast justified during a CO₂-first procedure?
Fallback to micro-doses of iodinated contrast is justified when, despite optimization of CO₂ injection parameters and imaging technique, CO₂ angiography cannot reliably identify the target lesion, safely support a critical interventional step, or distinguish between imaging artifacts and true vascular pathology. Every use of iodinated contrast should be supported by a clearly documented clinical rationale, and the cumulative contrast volume should remain within the patient's individualized maximum threshold.
Which technical parameters should be used for CO₂ injection in peripheral arteries?
Recommended injection parameters depend on the vascular territory. Typical starting settings include injection volumes of 20–30 mL for the infrarenal aorta and iliac arteries, with maximum pressures of 100–150 mmHg and flow rates of 15–20 mL/s. For femoropopliteal and distal arteries, lower injection volumes (10–20 mL) and reduced flow rates (8–12 mL/s) are generally appropriate. An automated CO₂ injection system ensures consistent delivery of these parameters while automatically recording them for procedural traceability.
How is the maximum safe iodinated contrast dose calculated in patients with CKD?
A commonly used reference formula is: Maximum contrast volume (mL) = 5 × body weight (kg) / serum creatinine (mg/dL). This value should be calculated before the procedure, documented in the patient's medical record, and used as the upper limit for cumulative iodinated contrast volume whenever fallback becomes necessary. In patients with severely reduced renal function (eGFR <30 mL/min/1.73 m²), the preferred objective is to maintain iodinated contrast exposure as close to zero as possible through a Zero Contrast strategy.
Which technical errors should be avoided during CO₂ angiography?
The most common technical errors include uncontrolled manual injection (which increases the risk of over-distension and gas embolism), air contamination within the delivery circuit, use of non-medical-grade CO₂, excessively high DSA frame rates that degrade image quality, and incorrect patient positioning. The use of a certified automated CO₂ injection system substantially reduces these technical risks by standardizing gas delivery and minimizing operator-dependent variability.
Why is documentation of every CO₂ injection important for clinical governance?
Systematic documentation of injection parameters—including CO₂ volume, iodinated contrast volume, image quality, and the clinical rationale for any fallback—enables healthcare teams to evaluate the long-term impact of a CO₂-first strategy on renal outcomes, identify opportunities for workflow improvement, and develop a robust institutional database for Health Technology Assessment (HTA), quality improvement initiatives, and participation in multicenter clinical registries. Comprehensive traceability also supports regulatory compliance, clinical audits, and structured multidisciplinary case review.
